MedTech - Truist Securities MedTech Conference Key Fireside/Discussion Takeaways

Research evidence excerpt

MedTech - Truist Securities MedTech Conference Key Fireside/Discussion Takeaways

evenue and effectively de-risks the impact of CMS reimbursement volatility affecting

the physician office/ASC care settings in 2026. And in the latter segment, mgmt. views the CMS fallout as a "leveling of the economic

playing field," as IART's pricing was already in-line with new mandates and their broad portfolio and allows them to capture volume

from other manufacturers that may be exiting the space.

iRhythm (IRTC, BUY) - MCT approval timeline remains on track for 1H27. Mgmt. also provided its first public comments around the

cybersecurity incident (announced 6/15) and does not anticipate any operational, financial, or regulatory approval timing impact.

• The cybersecurity incident (announced 6/15) appears largely contained and isolated with no operational, financial or

regulatory impact expected. Mgmt. provided its first public comments regarding the 6/15 cybersecurity incident announcement that

was identified on June 8th. The company clarified that a "threat actor" accessed patient data and other proprietary data, which triggered

its cybersecurity response plan involving bringing in outside cybersecurity experts to contain and investigate the breach. Mgmt. stressed

there has been no impact to its products, operations, or patient safety and based on what it knows today, it does not expect a material

impact to its current guidance. The breach is not expected to impact MCT approval timeline either. The investigation is still

active and mgmt. will update investors if anything material emerges.

• Innovative channel partners (ICPs) remain IRTC’s fastest-growing channel and, in our view, one of the more underappreciated

long-term growth drivers in the story.